Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

SummaryBackgroundPembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the first-line setting. However, the optimal duration of anti-PD-1 administration is unknown. We present results from 5 years o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2019-09, Vol.20 (9), p.1239-1251
Hauptverfasser:	Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Colitis Cytotoxicity Diarrhea Dosage Hematology, Oncology, and Palliative Medicine Immunotherapy Intravenous administration Lymphatic system Medical prognosis Melanoma Monoclonal antibodies Oncology Patients PD-1 protein Pembrolizumab Sepsis Survival Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!